for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Acorda Therapeutics Inc

ACOR.OQ

Latest Trade

1.87USD

Change

0.11(+5.97%)

Volume

53,829

Today's Range

1.76

 - 

1.91

52 Week Range

1.50

 - 

17.55

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.76
Open
1.77
Volume
53,829
3M AVG Volume
35.40
Today's High
1.91
Today's Low
1.76
52 Week High
17.55
52 Week Low
1.50
Shares Out (MIL)
48.03
Market Cap (MIL)
81.17
Forward P/E
-0.23
Dividend (Yield %)
--

Next Event

Q4 2019 Acorda Therapeutics Inc Earnings Release

Latest Developments

More

Acorda Therapeutics Reports Q3 Results

Acorda Therapeutics Implements Corporate Restructuring, Provides Q3 Update

Acorda Therapeutics Says Intends To Provide Additional Inbrija Launch Updates On Q3 2019 Conference Call

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Acorda Therapeutics Inc

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.

Industry

Biotechnology & Drugs

Contact Info

420 Saw Mill River Rd

+1.914.3474300

http://www.acorda.com

Executive Leadership

Ron Cohen

President,Chief Executive Officer, Director

David Lawrence

Chief Business Operations, Principal Accounting Officer

Jane G. Wasman

President - International, General Counsel, Corporate Secretary

Burkhard Blank

Chief Medical Officer and Head of R&D

Lauren M. Sabella

Chief Commercial Officer

Key Stats

3.14 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.5K

2017

0.6K

2018

0.5K

2019(E)

0.2K
EPS (USD)

2016

0.250

2017

1.750

2018

2.180

2019(E)

-2.130
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.38
Price To Book (MRQ)
0.29
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
124.93
LT Debt To Equity (MRQ)
124.72
Return on Investment (TTM)
-35.03
Return on Equity (TTM)
-31.39

Latest News

Latest News

U.S. Supreme Court rejects Acorda appeal in MS drug patent fight

The U.S. Supreme Court on Monday declined to hear Acorda Therapeutics Inc's appeal of a lower court ruling that allowed generic versions of its multiple sclerosis treatment Ampyra and caused the drug's sales to plummet.

U.S. Supreme Court rejects Acorda appeal in MS drug patent fight

The U.S. Supreme Court on Monday declined to hear Acorda Therapeutics Inc's appeal of a lower court ruling that allowed generic versions of its multiple sclerosis treatment Ampyra and caused the drug's sales to plummet.

U.S. appeals court invalidates Acorda patents on MS drug

A U.S. appeals court on Monday invalidated Acorda Therapeutics Inc patents covering its multiple sclerosis drug Ampyra, opening the door to generic competition for the company's flagship product.

Acorda loses bid for U.S. court order halting generic Ampyra sales

A U.S. appeals court on Wednesday denied a request by Acorda Therapeutics Inc for a temporary court order blocking generic drug companies from launching lower-cost versions of its multiple sclerosis drug Ampyra.

BRIEF-Acorda Therapeutics Reports Q1 Non-GAAP Earnings Per Share Of $0.14

* ACORDA PROVIDES FINANCIAL AND PIPELINE UPDATE FOR FIRST QUARTER 2018

BRIEF-Axsome Therapeutics Appoints Nick Pizzie, Cpa, Mba, As Chief Financial Officer

* AXSOME THERAPEUTICS APPOINTS NICK PIZZIE, CPA, MBA, AS CHIEF FINANCIAL OFFICER

BRIEF-Abeona Therapeutics Appoints Carsten Thiel, Ph.D., As Chief Executive Officer

* ABEONA THERAPEUTICS APPOINTS CARSTEN THIEL, PH.D., AS CHIEF EXECUTIVE OFFICER

BRIEF-Acorda Files Marketing Authorization Application For Inbrija

* ACORDA FILES MARKETING AUTHORIZATION APPLICATION FOR INBRIJA™ (LEVODOPA INHALATION POWDER)

BRIEF-Leap Therapeutics Provides Dkn-01 Program Update

* LEAP THERAPEUTICS PROVIDES DKN-01 PROGRAM UPDATE AND ANNOUNCES SCIENTIFIC PRESENTATIONS AT AACR ANNUAL MEETING

BRIEF-Acorda Enters Into Cooperation Agreement With Scopia

* ACORDA THERAPEUTICS INC - UNDER TERMS, AFTER 2018 ANNUAL MEETING AND UNTIL JAN 1, 2019, SCOPIA IS ENTITLED TO APPOINT 2 DIRECTORS TO CO'S BOARD

BRIEF-Acorda Announces FDA Acceptance Of New Drug Application For Inbrija

* ACORDA ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR INBRIJA™ (LEVODOPA INHALATION POWDER)

BRIEF-Acorda Therapeutics Q4 Adj Shr $0.61

* AMPYRA NET REVENUE IS EXPECTED TO BE $330 MILLION TO $350 MILLION IN 2018

Acorda Therapeutics exploring sale: WSJ

Acorda Therapeutics <ACOR.O> is exploring a sale of the company, the Wall Street Journal reported, citing people familiar with the matter.

BRIEF-Acorda Therapeutics Is Exploring A Potential Sale - WSJ, Citing Sources

* ACORDA THERAPEUTICS IS EXPLORING A POTENTIAL SALE - WSJ, CITING SOURCES Source text - http://on.wsj.com/2Ay49BA Further company coverage: (Bengaluru Newsroom)

BRIEF-Acorda Resubmits New Drug Application For INBRIJA

* ACORDA RESUBMITS NEW DRUG APPLICATION FOR INBRIJA™ (CVT-301, LEVODOPA INHALATION POWDER)

Acorda Therapeutics scraps Parkinson's drug after deaths

Acorda Therapeutics Inc said on Monday it would stop developing its Parkinson's disease drug, tozadenant, less than a week after the company reported deaths in key studies testing the treatment.

Acorda Therapeutics scraps development of Parkinson's disease drug

Acorda Therapeutics Inc said on Monday it would terminate developing its drug to treat Parkinson's disease, a week after the drugmaker reported five deaths in key studies testing the treatment.

BRIEF-Acorda announces royalty monetization transactions for $53 mln

* Acorda announces royalty monetization transactions for $53 million

Acorda reports five deaths in Parkinson's trial, shares plunge

Acorda Therapeutics Inc said five people died in trials for its Parkinson's disease drug, the latest in a series of setbacks for the drugmaker, sending its shares down 38 percent.

BRIEF-Acorda provides update on tozadenant development program

* Identified cases of agranulocytosis, possibly drug-related, in some cases associated with sepsis and death

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up